The Harvard Biomarkers Study Biobank is one of the world’s largest biobanks for Parkinson’s disease, Alzheimer’s disease, and related neurodegenerative diseases. More than 200,000 biosamples from 3,000 deeply characterized patients allow the discovery of new targets for drugs, new genes, and new diagnostics. Unique iPSC capability enables drug screening using patient’s cells with linked biomarkers, genomes, and clinical phenotypes.

Harnessing the power of collaboration

The biobank speeds up research for biomarkers from years to months at a fraction of cost. We believe that when we work together we can make progress, faster. Therefore, we now are making this treasure trove available to qualified scientists around the world.

Are you curious to learn more? Check out our recent publications here!

Are you ready to make discoveries?

Apply for biosamples in three easy steps.

The Harvard Biomarkers Study Biobank is temporarily closed for collaborations until early 2024. 

Please email Dr. Beatrice Weykopf at with any questions.


Click here to add your own text